As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the ...

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

Datroway is the second ADC brought to market by AZ and Daiichi Sankyo after Enhertu (trastuzumab deruxtecan), an HER2-targeting ADC that brought in sales of more than $2.7 billion in the first ...

Daiichi Sankyo originated Datroway and has exclusive ownership of the drug in Japan, but licensed co-development rights in other markets to AstraZeneca in 2020 for $1 billion upfront, plus up to $ ...

Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong ...

How Does Datroway Work for Breast Cancer? Datroway is a type of medicine known as an antibody drug conjugate (ADC). The ADC is designed to deliver medicine directly to the cancer cells and is made ...

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain ... Vandana Singh FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients AstraZeneca's Datroway gains FDA approval ...